Context Therapeutics Inc is trading at $0.64 (6.4% down) in pre-market, extending a sharp sell-off following the release of interim Phase 1 data for its ovarian cancer candidate, CTIM-76.
- The stock is seeing continued downward momentum after a steep 51% decline in the previous session, which saw the price fall from $1.39 to $0.68.
- Although the June 15, 2026, announcement highlighted favorable efficacy and safety signals, the data triggered significant volatility and profit-taking among investors.